NCT01725100 - A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 5, 2013

Primary Completion Date

January 30, 2015

Study Completion Date

January 30, 2015

Conditions

Cancer

Interventions

DRUG

GSK1120212B (Standard DMSO content)

Each tablet contains GSK1120212B equivalent to 2 mg of GSK1120212 as drug substance. The coated tablets have a standard DMSO content of theoretical 11.3%.

DRUG

GSK1120212B (Lower DMSO content)

Each tablet contains GSK1120212B equivalent to 2 mg of GSK1120212 as drug substance. The coated tablets have a lower DMSO content approximately 9.5%.

Trial Locations (4)

34232

GSK Investigational Site, Sarasota

37203

GSK Investigational Site, Nashville

85259

GSK Investigational Site, Scottsdale

85338

GSK Investigational Site, Goodyear